Acadia Pharmaceuticals Again Prevails in Appeal Upholding Patent for Parkinson's Drug

 Composition of matter patent affirmed, provides protection into 2030

- Builds on recent ruling in favor of Acadia for formulation patent expiring in 2038

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Court of Appeals for the Federal Circuit affirmed a decision issued by the U.S. District Court for the District of Delaware in December 2023 confirming validity of the NUPLAZID® (pimavanserin) '740 composition of matter patent. The affirmance came in Acadia’s litigation against MSN Laboratories Pvt. Ltd. and MSN Pharmaceuticals, Inc.

https://finance.yahoo.com/news/u-court-appeals-federal-circuit-200100101.html